LON:DPH Dechra Pharmaceuticals (DPH) Share Forecast, Price & News GBX 3,788 -8.00 (-0.21%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range 3,788▼ 3,81450-Day Range 3,688▼ 3,81652-Week Range 2,473.32▼ 4,145.84Volume234,441 shsAverage Volume916,604 shsMarket Capitalization£4.31 billionP/E Ratio10,522.22Dividend Yield1.19%Price TargetGBX 3,606.40 ProfileProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlines Dechra Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside4.8% DownsideGBX 3,606.40 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.84 out of 5 stars 1.4 Analyst's Opinion Consensus RatingDechra Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 3,606.40, Dechra Pharmaceuticals has a forecasted downside of 4.8% from its current price of GBX 3,788.Amount of Analyst CoverageDechra Pharmaceuticals has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DPH. Previous Next 0.8 Dividend Strength Dividend YieldDechra Pharmaceuticals pays a meaningful dividend of 1.19%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthDechra Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dechra Pharmaceuticals is 12,500.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DPH. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Dechra Pharmaceuticals this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dechra Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.43% of the stock of Dechra Pharmaceuticals is held by insiders.Percentage Held by Institutions85.98% of the stock of Dechra Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Dechra Pharmaceuticals is 10,522.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 117.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Dechra Pharmaceuticals is 10,522.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 121.93.Price to Earnings Growth RatioDechra Pharmaceuticals has a PEG Ratio of 1.42. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDechra Pharmaceuticals has a P/B Ratio of 5.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dechra Pharmaceuticals (LON:DPH) StockDechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.Read More DPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DPH Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comDechra Pharmaceuticals (LON:DPH) Stock Price Crosses Above 200 Day Moving Average of $3,519.62September 29, 2023 | finance.yahoo.comForm 8.3 - DPH LN Equity 28-September-23 Dealing DisclosureSeptember 30, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...September 21, 2023 | marketwatch.comDechra Pharmaceuticals falls Thursday, still outperforms marketSeptember 21, 2023 | americanbankingnews.comDechra Pharmaceuticals (LON:DPH) Share Price Crosses Above 200-Day Moving Average of $3,470.27September 20, 2023 | finance.yahoo.comForm 8.3 - Dechra Pharmaceuticals plc - AmendmentSeptember 15, 2023 | finance.yahoo.comForm 8.3 - DPH LN Equity 14-September-23 Dealing DisclosureAugust 31, 2023 | markets.businessinsider.comBack in the Big League: M&S Rejoins the FTSE 100 on Share Price BoostSeptember 30, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...August 22, 2023 | finance.yahoo.comMarks & Spencer Set for FTSE 100 Comeback After This Year’s 78% Share Price RiseAugust 15, 2023 | marketwatch.comDechra Pharmaceuticals remains steady Tuesday, still outperforms marketJuly 20, 2023 | bloomberg.comDPH: Carlson Capital, L.P.: Form 8.3 - Dechra Pharmaceuticals plcJuly 12, 2023 | finance.yahoo.comForm 8.3 - DPH LN Equity 11-July-23 Increase in Traded PositionJuly 6, 2023 | marketwatch.comDechra Pharmaceuticals remains steady Thursday, still outperforms marketJuly 6, 2023 | finance.yahoo.comDCHPF - Dechra Pharmaceuticals PLCJuly 5, 2023 | marketwatch.comDechra Pharmaceuticals outperforms market despite losses on the dayJuly 3, 2023 | finance.yahoo.comForm 8.3 - DPH LN Equity 30-June-23 Increase in Traded PositionJune 28, 2023 | finance.yahoo.comForm 8.3 - DPH LN Equity 27-June-23 Dealing DisclosureJune 6, 2023 | finance.yahoo.comForm 8.3 - Dechra Pharmaceuticals PLC [DPH LN]June 6, 2023 | finance.yahoo.comForm 8.3 - Dechra PharmaceuticalsJune 5, 2023 | finance.yahoo.comForm 8.3 - DPH LNJune 3, 2023 | reuters.comEQT ups bet on pet industry with $5.6 bln Dechra dealJune 2, 2023 | msn.comThe Dechra share price holds a lesson for all investors!May 28, 2023 | msn.comDeutsche Reiterates Dechra Pharmaceuticals (LSE:DPH) Outperform RecommendationMay 26, 2023 | finance.yahoo.comForm 8.3 - DECHRA PHARMAMay 24, 2023 | msn.comEuropean stocks muted as U.S. debt ceiling concerns lingerMay 23, 2023 | msn.comUK's Dechra slumps after profit warningSee More Headlines Receive DPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers—General Sub-IndustryN/A SectorMedical Current SymbolLON:DPH CUSIPN/A CIKN/A Webwww.dechra.com Phone+44-1606-814730FaxN/AEmployees1,998Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 3,606.40 High Stock Price ForecastGBX 4,070 Low Stock Price ForecastGBX 2,850 Forecasted Upside/Downside-4.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.36 Trailing P/E Ratio10,522.22 Forward P/E Ratio20.32 P/E Growth1.42Net Income£40.10 million Net Margins5.52% Pretax MarginN/A Return on Equity5.42% Return on Assets3.65% Debt Debt-to-Equity Ratio60.73 Current Ratio2.73 Quick Ratio1.66 Sales & Book Value Annual Sales£726.80 million Price / Sales5.94 Cash FlowGBX 155.05 per share Price / Cash Flow24.43 Book ValueGBX 744 per share Price / Book5.09Miscellaneous Outstanding Shares113,890,000Free FloatN/AMarket Cap£4.31 billion OptionableNot Optionable Beta0.79 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Ian D. Page (Age 62)CEO, MD & Exec. Director Comp: $1.26MMr. Paul Nicholas Sandland MAAT (Age 44)FCCA, CFO & Exec. Director Comp: $790kDr. Anthony Gerard Griffin (Age 60)MD of Dechra Veterinary Products for Europe & Exec. Director Comp: $601kMr. Patrick MeeusGroup Scientific OfficerMr. Jamie AdamsChief Information OfficerMs. Katy CloughGroup HR DirectorMr. Mike Eldred (Age 53)Pres of North America Ms. Melanie Jane HallCompany Sec.More ExecutivesKey CompetitorsConvaTec GroupLON:CTECHikma PharmaceuticalsLON:HIKMediclinic InternationalLON:MDCBTGLON:BTGAbcamLON:ABCView All CompetitorsInsidersLisa BrightBought 585 shares on 10/12/2022Total: £1.50 M ($2,558.00/share)John ShipseyBought 600 shares on 10/7/2022Total: £1.52 M ($2,529.00/share)View All Insider Transactions DPH Stock - Frequently Asked Questions Should I buy or sell Dechra Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DPH shares. View DPH analyst ratings or view top-rated stocks. What is Dechra Pharmaceuticals' stock price forecast for 2023? 5 Wall Street research analysts have issued 1-year price objectives for Dechra Pharmaceuticals' shares. Their DPH share price forecasts range from GBX 2,850 to GBX 4,070. On average, they predict the company's share price to reach GBX 3,606.40 in the next year. This suggests that the stock has a possible downside of 4.8%. View analysts price targets for DPH or view top-rated stocks among Wall Street analysts. How have DPH shares performed in 2023? Dechra Pharmaceuticals' stock was trading at GBX 2,618 on January 1st, 2023. Since then, DPH stock has increased by 44.7% and is now trading at GBX 3,788. View the best growth stocks for 2023 here. How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals? Dechra Pharmaceuticals announced a dividend on Monday, February 27th. Shareholders of record on Thursday, March 9th will be paid a dividend of GBX 12.50 per share on Thursday, April 13th. This represents a dividend yield of 0.4%. The ex-dividend date is Thursday, March 9th. The official announcement can be accessed at this link. Read our dividend analysis for DPH. Is Dechra Pharmaceuticals a good dividend stock? Dechra Pharmaceuticals (LON:DPH) pays an annual dividend of GBX 45 per share and currently has a dividend yield of 1.19%. The dividend payout ratio is 12,500.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for DPH. What other stocks do shareholders of Dechra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV). What is Dechra Pharmaceuticals' stock symbol? Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH." How do I buy shares of Dechra Pharmaceuticals? Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Dechra Pharmaceuticals' stock price today? One share of DPH stock can currently be purchased for approximately GBX 3,788. How much money does Dechra Pharmaceuticals make? Dechra Pharmaceuticals (LON:DPH) has a market capitalization of £4.31 billion and generates £726.80 million in revenue each year. The company earns £40.10 million in net income (profit) each year or GBX 0.36 on an earnings per share basis. How many employees does Dechra Pharmaceuticals have? The company employs 1,998 workers across the globe. How can I contact Dechra Pharmaceuticals? Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The official website for the company is www.dechra.com. The company can be reached via phone at +44-1606-814730. This page (LON:DPH) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dechra Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.